Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Abstract: The present invention provides a crystalline form and stable salts of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1- piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several hydrochloride salt forms, phosphate salt form, mesylate salt form, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.

Abstract: This disclosure relates to a pre-assembled fastener assembly having a retainer, a nut member, and a cold expansion mandrel that is forcibly removable after the assembly is installed into an opening of a structural workpiece. The mandrel is captured between a portion of a retainer and a portion of a nut member. The forced removal of the mandrel expands the retainer into the opening, securing the fastener assembly therein. The assembly may also include a cap coupled to the retainer to seal the opening in the structural workpiece. The nut member can be fixed or free-floating with respect to the retainer. In addition, the nut member can be threaded to receive a fastener. The mandrel is recyclable or disposable.

Abstract: A sealed attachment fastener assembly with a receiving member and a cap that can be inserted into an opening in a work piece and fixed therein from only one side of the work piece. A portion of the fastener assembly on the blind side of the work piece is collapsible into a flange. In addition, another portion of the fastener assembly is contemporaneously radially expandable within the opening of the work piece to at least rotationally secure the fastener assembly with respect to the work piece. The radial expansion will result in a high interference fit of the fastener in the work piece, which may enhance the fatigue of the installation. A cap completes the fastener assembly to substantially prevent fluid from leaking through the fastener assembly opening. The cap can be assembled with the receiving member after the internal threads within the receiving member have been machined.

Abstract: A tubular fastener element is inserted into an opening in a wall until a flange at the trailing end of the fastener element is in contact with the wall. Then, an externally threaded end of a rod is inserted into a center opening in the fastener element from the flange side of the wall and is mated with internal threads in the fastener element beyond the second side of the wall. A tubular mandrel that surrounds the rod is moved into contact with the entrance portion of the center opening in the tubular fastener. The outside diameter of the mandrel is larger than the inside diameter of the center opening in the fastener element. The rod is retracted to cause a reduced thickness wall portion of the fastener element to collapse and form a second radial flange on the second side of the wall. The mandrel is forced axially into the center opening in the fastener element.